Veronica Conca

1.1k total citations
34 papers, 202 citations indexed

About

Veronica Conca is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Veronica Conca has authored 34 papers receiving a total of 202 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Veronica Conca's work include Colorectal Cancer Treatments and Studies (25 papers), Genetic factors in colorectal cancer (14 papers) and Cancer Genomics and Diagnostics (7 papers). Veronica Conca is often cited by papers focused on Colorectal Cancer Treatments and Studies (25 papers), Genetic factors in colorectal cancer (14 papers) and Cancer Genomics and Diagnostics (7 papers). Veronica Conca collaborates with scholars based in Italy, France and Malaysia. Veronica Conca's co-authors include Carlotta Antoniotti, Gianluca Masi, Marco Maria Germani, Beatrice Borelli, Chiara Cremolini, Filippo Pietrantonio, Daniele Rossini, Sara Lonardi, Alessandra Boccaccino and Alberto Zaniboni and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Veronica Conca

30 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veronica Conca Italy	9	144	57	49	45	33	34	202
F. Losa Gaspà Spain	4	136 0.9×	60 1.1×	62 1.3×	23 0.5×	35 1.1×	9	188
Arteid Memaj United States	8	205 1.4×	108 1.9×	69 1.4×	57 1.3×	33 1.0×	17	283
Keigo Chida Japan	6	138 1.0×	57 1.0×	62 1.3×	52 1.2×	27 0.8×	18	194
Makoto Ueno Japan	9	138 1.0×	27 0.5×	77 1.6×	115 2.6×	27 0.8×	31	234
E. Falcó Spain	10	176 1.2×	39 0.7×	136 2.8×	65 1.4×	44 1.3×	37	292
Johan M. van Rooijen Netherlands	8	145 1.0×	39 0.7×	58 1.2×	38 0.8×	49 1.5×	16	224
Sara Hafezi‐Bakhtiari Canada	9	132 0.9×	88 1.5×	86 1.8×	90 2.0×	32 1.0×	24	264
Antonio Pellino Italy	6	118 0.8×	46 0.8×	85 1.7×	111 2.5×	59 1.8×	10	224
Ahmad Al-Sukaini United Kingdom	5	143 1.0×	26 0.5×	46 0.9×	116 2.6×	25 0.8×	8	188
Sreelakshmi Mallappa United Kingdom	6	146 1.0×	26 0.5×	32 0.7×	69 1.5×	50 1.5×	14	219

Countries citing papers authored by Veronica Conca

Since Specialization

Citations

This map shows the geographic impact of Veronica Conca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Conca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Conca more than expected).

Fields of papers citing papers by Veronica Conca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Conca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Conca. The network helps show where Veronica Conca may publish in the future.

Co-authorship network of co-authors of Veronica Conca

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Conca. A scholar is included among the top collaborators of Veronica Conca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Conca. Veronica Conca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.

Rossini, Daniele, Lisa Salvatore, Sara Lonardi, et al.. (2025). Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. ESMO Open. 10(2). 104135–104135. 2 indexed citations

Conca, Veronica, Paola Vignali, Daniele Rossini, et al.. (2024). Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.. Journal of Clinical Oncology. 42(16_suppl). 3572–3572.

Conca, Veronica, Roberto Moretto, Sara Lonardi, et al.. (2024). Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.. Journal of Clinical Oncology. 42(16_suppl). TPS3644–TPS3644. 1 indexed citations

Conca, Veronica, Roberto Moretto, Carlotta Antoniotti, et al.. (2024). Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.. Journal of Clinical Oncology. 42(16_suppl). 3558–3558. 1 indexed citations

Conca, Veronica, et al.. (2024). Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials. Cancer Treatment Reviews. 126. 102735–102735. 12 indexed citations

Formica, Vincenzo, Cristina Morelli, Veronica Conca, et al.. (2023). Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers. 15(11). 3064–3064. 2 indexed citations

Fanotto, V., Daniele Rossini, Mariaelena Casagrande, et al.. (2023). Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers. 15(22). 5451–5451. 1 indexed citations

Marmorino, Federica, Gianmarco Piccinno, Daniele Rossini, et al.. (2023). Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.. Journal of Clinical Oncology. 41(16_suppl). 3534–3534. 2 indexed citations

10.

Antoniotti, Carlotta, Daniele Rossini, Filippo Pietrantonio, et al.. (2023). SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study. Annals of Oncology. 34. S173–S174. 2 indexed citations

11.

Chia, Daryl Kai Ann, Leonardo Provenzano, Sara Lonardi, et al.. (2023). Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer.. Journal of Clinical Oncology. 41(4_suppl). 455–455.

12.

Moretto, Roberto, Marco Maria Germani, Mirella Giordano, et al.. (2023). Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development. British Journal of Cancer. 128(7). 1391–1399. 14 indexed citations

13.

Conca, Veronica, Carlotta Antoniotti, Francesca Bergamo, et al.. (2023). Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.. Journal of Clinical Oncology. 41(16_suppl). 3575–3575. 5 indexed citations

14.

Rossini, Daniele, Marco Maria Germani, Sara Lonardi, et al.. (2022). Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. European Journal of Cancer. 170. 64–72. 11 indexed citations

15.

Moretto, Roberto, Daniele Rossini, Iolanda Capone, et al.. (2021). Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer. 20(4). 314–317. 12 indexed citations

16.

Moretto, Roberto, Daniele Rossini, Veronica Conca, et al.. (2021). CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British Journal of Cancer. 125(6). 839–845. 10 indexed citations

17.

Lai, Eleonora, Marco Puzzoni, Pina Ziranu, et al.. (2021). Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer. 20(4). e253–e262. 2 indexed citations

18.

Lombardi, Pasquale, Daniele Rossini, Marco Maria Germani, et al.. (2021). Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treatment Reviews. 103. 102326–102326. 8 indexed citations

19.

Lonardi, Sara, Filippo Pietrantonio, Alessandra Anna Prete, et al.. (2020). 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. Annals of Oncology. 31. S412–S412. 13 indexed citations

20.

Picciotto, A., Francesco Callea, Veronica Conca, et al.. (1995). Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver International. 15(1). 20–24. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact